The global GI stool testing market is anticipated to grow at a considerable CAGR of 7.1% during the forecast period (2022-2028). Gastrointestinal infections (GI) are caused by a variety of viruses, bacteria, and parasites. The gastrointestinal pathogen panel simultaneously tests for the presence of multiple disease-causing (pathogenic) microbes in a stool sample. The GI pathogen panel detects the genetic material (RNA or DNA) of some of the more common pathogens. It can identify co-infections (more than one microbe causing the infection) and identify microbes that might be missed with traditional testing. The rising prevalence of diarrhea across the globe is expected to raise the demand for the GI stool testing market during the forecast period. For instance, according to the World Health Organization, diarrheal disease is the second leading cause of death in children under five years old. Globally, there are nearly 1.7 billion cases of childhood diarrheal disease every year. Moreover, each year diarrhea kills around 5,25,000 children under five.
Browse the full report description of “GI Stool Testing Market Size, Share & Trends Analysis Report by Product Type (Instruments and Reagents), by Test Type (Microscopy, Occult Blood Test, Ova and Parasites Test, Bacteria Test, Fecal Biomarkers Test, and Other Test Types), by End-Users (Hospitals, Home, Diagnostic Centers & Laboratories, and Academic Institutions and Research Centers) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/gi-stool-testing-market
The technological advancements by market players across the globe are expected to hold a prominent share of the market during the forecast period. For instance, in January 2022, Exact Sciences Corp. announced performance data for a second-generation Cologuard (multi-target stool DNA) test showing overall sensitivity of 95.2% for colorectal cancer (CRC) at the specificity of 92.4% for negative samples confirmed by colonoscopy. Furthermore, Cologuard is the first and only FDA-approved, non-invasive stool DNA test used to screen average-risk people for CRC. Exact Sciences is developing a second-generation Cologuard to improve the specificity and precancer sensitivity of the test, decreasing the false positive rate and increasing the detection rate of precancerous lesions.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Product Type
o By Test Type
o By End-Users
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- including Abbott Laboratories, Alere, Inc., Cardinal Health, Inc., Cenogenics Corp., DiaSorin S.p.A, Diagnostic Solutions Laboratory, LLC, Epitope Diagnostics Inc., Siemens Healthcare, and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
o Deviation from the pre-COVID-19 forecast
o Most affected regions and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global GI Stool Testing Market Report Segment
By Product Type
By Test Type
By End-Users
Global GI Stool Testing Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/gi-stool-testing-market